Jump to content

Surufatinib

From Wikipedia, the free encyclopedia

Surufatinib
Clinical data
Trade namesSulanda
Other namesSulfatinib; HMPL-012
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • N-[2-(Dimethylamino)ethyl]-1-[3-[[4-[(2-methyl-1H-indol-5-yl)oxy]pyrimidin-2-yl]amino]phenyl]methanesulfonamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC24H28N6O3S
Molar mass480.59 g·mol−1
3D model (JSmol)
  • CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C
  • InChI=1S/C24H28N6O3S/c1-17-13-19-15-21(7-8-22(19)27-17)33-23-9-10-25-24(29-23)28-20-6-4-5-18(14-20)16-34(31,32)26-11-12-30(2)3/h4-10,13-15,26-27H,11-12,16H2,1-3H3,(H,25,28,29)
  • Key:TTZSNFLLYPYKIL-UHFFFAOYSA-N

Surufatinib (trade name Sulanda) is pharmaceutical drug for the treatment of cancer. In China, it is approved for late-stage, well-differentiated, extrapancreatic neuroendocrine tumors.[1]

It is also under investigation for the treatment of other types of solid tumors.[2][3]

Surufatinib targets fibroblast growth factor receptor 1 (FGFR1).[4]

References

[edit]
  1. ^ Syed YY (April 2021). "Surufatinib: First Approval". Drugs. 81 (6): 727–732. doi:10.1007/s40265-021-01489-y. PMID 33788183.
  2. ^ Liao S, Li J, Gao S, Han Y, Han X, Wu Y, et al. (2023). "Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1-3, suppresses osteosarcoma proliferation and invasion via dual role in tumor cells and tumor microenvironment". Frontiers in Oncology. 13: 1158857. doi:10.3389/fonc.2023.1158857. PMC 10286821. PMID 37361567.
  3. ^ Xu JM, Wang Y, Chen YL, Jia R, Shen L, Wang J, et al. (2014). "First-in-human (FIH) phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors". Journal of Clinical Oncology. 32 (15_suppl): 2615. doi:10.1200/jco.2014.32.15_suppl.2615.
  4. ^ Lin Q, Dai S, Qu L, Lin H, Guo M, Wei H, et al. (January 2024). "Structural basis and selectivity of sulfatinib binding to FGFR and CSF-1R". Communications Chemistry. 7 (1): 3. doi:10.1038/s42004-023-01084-0. PMC 10764862. PMID 38172256.